<DOC>
	<DOCNO>NCT00343811</DOCNO>
	<brief_summary>The purpose study evaluate continue efficacy modafinil treatment , compare placebo treatment , child adolescent attention-deficit/hyperactivity disorder ( ADHD ) responders modafinil treatment .</brief_summary>
	<brief_title>Study Evaluate Efficacy Modafinil Treatment Patients With Attention Deficit Hyperactivity Disorder ( ADHD ) Who Are Responders Modafinil Treatment</brief_title>
	<detailed_description>The primary objective study evaluate continue efficacy modafinil treatment , compare placebo treatment , child adolescent attention-deficit/hyperactivity disorder ( ADHD ) responders modafinil treatment , assess change baseline ( current study ) total score ADHD Rating Scale , Fourth Edition ( ADHD-RS-IV ) ( Home Version ) endpoint ( week 6 last double-blind post-baseline visit ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Patients must currently enrol Cephalonsponsored clinical study complete least 12 month continuous modafinil treatment . Patients include study continue meet applicable criterion previous study follow criterion meet : Written inform consent/assent obtain . The patient currently enrol study C1538d/312/AD/US C1538/3044/AD/US receive modafinil treatment , continuously , least 12 month . The patient meet protocol criterion response last 2 visit previous study . Patients study C1538d/312/AD/US must least 25 % reduction AttentionDeficit/Hyperactivity Disorder Rating Scale IV [ ADHDRSIV ] ( Home Version ) total score compare original baseline ( must baseline previous doubleblind , placebocontrolled study modafinil ADHD ) . Patients study C1538/3044/AD/US must least 25 % reduction total score ADHD Index subscale Conners ' Parent Rating Scale : Revised , Short Form ( CPRS : RS ) , compare baseline value study C1538/3044/AD/US . The patient good health ( except diagnosis ADHD ) determine medical psychiatric history , physical examination , electrocardiogram ( ECGs ) , serum chemistry , hematology , urinalysis , vital sign . Girls postmenarche sexually active must negative urine pregnancy test baseline visit , must use medically acceptable method birth control , must agree continue use method duration study ( 30 day participation study ) . Acceptable method birth control include follow : barrier method spermicide ; steroidal contraceptive ( eg , oral , transdermal , implanted , inject ) conjunction barrier method ; intrauterine device ( IUD ) ; abstinence . The patient parent legal guardian willing participate study . Patients exclude participate study 1 follow criterion meet : The patient history current diagnosis pervasive developmental disorder , schizophrenia , psychotic disorder , positive clinical assessment current suicide risk ideation . The patient current psychiatric comorbidity require pharmacotherapy , include limited depression mood disorder , anxiety disorder , pervasive mental disorder . The patient currently use prescription medication , modafinil , ADHD ( eg , amphetamine , dextroamphetamine , methylphenidate , pemoline , atomoxetine ) . Previous exposure modafinil cause clinically significant ( drugrelated ) adverse reaction lead withdrawal study , investigator considers likely put patient risk .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Attention-Deficit/Hyper Activity Disorder</keyword>
	<keyword>ADHD</keyword>
</DOC>